Skip to main content
Fig. 3 | BMC Biology

Fig. 3

From: CLARITY increases sensitivity and specificity of fluorescence immunostaining in long-term archived human brain tissue

Fig. 3

Increased specificity of antibodies applied on CLARITY-processed sections. a MAP2 (frontal cortex) labeling in a perfusion-fixed case (case p2) plus (orange) and minus (blue) CLARITY treatment. Scale bars, 10 µm. b MAP2 labeling plus (orange) and minus (blue) CLARITY treatment in an immersion (i)-fixed brain with a comparable total fixation time as (a) (frontal cortex, case i1). Scale bars, 10 µm. c Numbers of dendrites with a length of 4–7 µm and > 7 µm were determined in two 2D images per case and condition. Average numbers of the two replicates are plotted per case (n = 6) for plus and minus CLARITY in the two categories (dendrite length 4–7 µm, top and > 7 µm, bottom). Importantly, for plus and minus CLARITY, tissue sections had been cut from the same block, which excludes a bias due to the orientation of the dendrites. Mann–Whitney test, P = 0.0022 (**). d Tyrosine hydroxylase labeling (caudate nucleus, case p2) plus (orange) and minus (blue) CLARITY treatment. Specific labeling is reflected by the intensity profiles (right) of the boxed areas (left, 1 and 2): matrix (M) and striosomes (S) are only discernible in the plus CLARITY profile (1). Mean intensities (int.) were normalized (norm.) to the maximum. A.u. = arbitrary unit. Scale bars, 500 µm (overview), 10 µm (magnified insets)

Back to article page